SCHEDULE 13G/A 0000902664-23-003735 0001603466 XXXXXXXX LIVE 5 Common Stock, par value $0.0001 per share 06/30/2025 0001689548 Praxis Precision Medicines, Inc. 74006W207 99 HIGH STREET, 30TH FLOOR BOSTON MA 02110 Rule 13d-1(c) Point72 Asset Management, L.P. b DE 0.00 1465105.00 0.00 1465105.00 1465105.00 N 7.0 PN Includes 511,030 shares of Common Stock (as defined in Item 2(a)) issuable upon exercise of warrants. Point72 Capital Advisors, Inc. b DE 0.00 1465105.00 0.00 1465105.00 1465105.00 N 7.0 CO Includes 511,030 shares of Common Stock issuable upon exercise of warrants. Point72 Biotech Private Investments, LLC b DE 0.00 65933.00 0.00 65933.00 65933.00 N 0.3 OO Differentiated Ventures Investments, LLC b DE 0.00 65933.00 0.00 65933.00 65933.00 N 0.3 OO 72 Investment Holdings, LLC b DE 0.00 65933.00 0.00 65933.00 65933.00 N 0.3 OO Steven A. Cohen b X1 0.00 1531038.00 0.00 1531038.00 1531038.00 N 7.3 IN Includes 511,030 shares of Common Stock issuable upon exercise of warrants. Praxis Precision Medicines, Inc. 99 High Street, 30th Floor Boston MA 02110 This statement is filed by: (i) Point72 Asset Management, L.P. ("Point72 Asset Management") with respect to the shares of common stock, par value $0.0001 per share ("Common Stock") of Praxis Precision Medicines, Inc. (the "Issuer") held by (and shares of Common Stock issuable upon exercise of the warrants held by) Point72 Associates, LLC, an investment fund it manages ("Point72 Associates"); (ii) Point72 Capital Advisors, Inc. ("Point72 Capital Advisors Inc.") with respect to the shares of Common Stock held by (and shares of Common Stock issuable upon exercise of the warrants held by) Point72 Associates; (iii) Point72 Biotech Private Investments, LLC ("Point72 Biotech") with respect to the shares of Common Stock of which it is the holder; (iv) Differentiated Ventures Investments, LLC ("Differentiated Ventures"), the managing member of Point72 Biotech, with respect to the shares of Common Stock held by Point72 Biotech; (v) 72 Investment Holdings, LLC ("72 Investment Holdings"), the sole member of Differentiated Ventures, with respect to the shares of Common Stock held by Point72 Biotech, and (vi) Steven A. Cohen ("Mr. Cohen") with respect to the shares of Common Stock beneficially owned by Point72 Asset Management, Point72 Capital Advisors Inc., Point72 Biotech, Differentiated Ventures, and 72 Investment Holdings. The address of the principal business office of Point72 Asset Management, Point72 Capital Advisors Inc., Point72 Biotech, Differentiated Ventures, 72 Investment Holdings, and Mr. Cohen is 72 Cummings Point Road, Stamford, CT 06902. Point72 Asset Management is a Delaware limited partnership. Point72 Capital Advisors Inc. is a Delaware corporation. Point72 Biotech, Differentiated Ventures, and 72 Investment Holdings are Delaware limited liability companies. Mr. Cohen is a United States citizen. Y The information required by Item 4(a) is set forth in Row 9 of the cover page for each of the Reporting Persons and is incorporated herein by reference. Such information is as of the close of business on June 30, 2025. Point72 Asset Management, Point72 Capital Advisors Inc., and Mr. Cohen own directly no shares of Common Stock. Pursuant to an investment management agreement, Point72 Asset Management maintains investment and voting power with respect to the securities held by Point72 Associates. Point72 Capital Advisors Inc. is the general partner of Point72 Asset Management. Mr. Cohen controls each of Point72 Asset Management and Point72 Capital Advisors Inc. Differentiated Ventures is the managing member of Point72 Biotech and may be deemed to share beneficial ownership over the shares of Common Stock held by Point72 Biotech. 72 Investment Holdings is the sole member of Differentiated Ventures and may be deemed to share beneficial ownership of the shares of Common Stock of which Differentiated Ventures may be deemed the beneficial owner. Mr. Cohen controls each of Point72 Biotech, Differentiated Ventures, and 72 Investment Holdings. The aggregate percentage of the shares of Common Stock reported to be beneficially owned by each Reporting Person as of June 30, 2025, is based on 20,880,012 shares of Common Stock outstanding, which is the sum of: (i) 20,368,982 shares of Common Stock outstanding as of April 30, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2025, filed with the Securities and Exchange Commission on May 2, 2025; and (ii) 511,030 shares of Common Stock issuable upon exercise of the warrants reported herein. The filing of this statement should not be construed as an admission that any of the foregoing persons or any Reporting Person is, for the purposes of Section 13 of the Securities Exchange Act of 1934, the beneficial owner of the shares of Common Stock reported herein. 7.3% The information required by Item 4(c)(i) is set forth in Row 5 of the cover page for each of the Reporting Persons and is incorporated herein by reference. Such information is as of the close of business on June 30, 2025. The information required by Item 4(c)(ii) is set forth in Row 6 of the cover page for each of the Reporting Persons and is incorporated herein by reference. Such information is as of the close of business on June 30, 2025. The information required by Item 4(c)(iii) is set forth in Row 7 of the cover page for each of the Reporting Persons and is incorporated herein by reference. Such information is as of the close of business on June 30, 2025. The information required by Item 4(c)(iv) is set forth in Row 8 of the cover page for each of the Reporting Persons and is incorporated herein by reference. Such information is as of the close of business on June 30, 2025. Y N See Item 2(a). Point72 Associates has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, more than 5 percent of the outstanding shares of Common Stock. Y Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. Point72 Asset Management, L.P. /s/ Jason M. Colombo 08/14/2025 Point72 Capital Advisors, Inc. /s/ Jason M. Colombo 08/14/2025 Point72 Biotech Private Investments, LLC /s/ Vincent Tortorella 08/14/2025 Differentiated Ventures Investments, LLC /s/ Vincent Tortorella 08/14/2025 72 Investment Holdings, LLC /s/ Jason M. Colombo 08/14/2025 Steven A. Cohen /s/ Jason M. Colombo 08/14/2025